Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,079,784,035
-
Number of holders
-
124
-
Total 13F shares, excl. options
-
33,071,782
-
Shares change
-
-2,424,263
-
Total reported value, excl. options
-
$123,053,543
-
Value change
-
-$11,174,770
-
Put/Call ratio
-
225%
-
Number of buys
-
69
-
Number of sells
-
55
-
Price
-
$3.72
Institutional Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q2 2022
157 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of 30 Jun 2022.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) had 124 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 33,071,782 shares of stock of the company.
Largest 10 holders included VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, JPMORGAN CHASE & CO, MORGAN STANLEY, CITADEL ADVISORS LLC, NORTHERN TRUST CORP, and CREDIT SUISSE AG/.
This table shows the top 124 institutional shareholders of the security as of 30 Jun 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.